"Cancersensor" Metastasis Resection
This study is currently recruiting participants.
Verified September 2012 by Institut National de la Santé Et de la Recherche Médicale, France
Sponsor:
Institut National de la Santé Et de la Recherche Médicale, France
Information provided by (Responsible Party):
Institut National de la Santé Et de la Recherche Médicale, France
ClinicalTrials.gov Identifier:
NCT01693848
First received: September 7, 2012
Last updated: September 24, 2012
Last verified: September 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Observational, non randomized study aimed at measuring the effect of surgical resection of metastasis in the urinary concentrations of physiological modified nucleosides in 45 patients with metastatic colorectal cancer.
| Condition |
|---|
|
Metastatic Colorectal Cancer |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Prospective |
| Official Title: | Molecularly Imprinted Polymer Sensors of Modified Nucleosides for Non-invasive Monitoring, of Cancer Therapy: Impact of Surgical Resection of Metastasis on Urinary Excretion of Modified Nucleosides. |
Resource links provided by NLM:
Further study details as provided by Institut National de la Santé Et de la Recherche Médicale, France:
Primary Outcome Measures:
- Effect of resection of metastasis on urinary excretion of modified nucleosides [ Time Frame: 10 days ] [ Designated as safety issue: No ]1 Urine sample per day 3 before and 7 after surgery Measurement of modified nucleoside concentration
Secondary Outcome Measures:
- Identification of modified nucleosides as biomarkers for colorectal cancer [ Time Frame: 10 days ] [ Designated as safety issue: No ]Measurement of modified nucleosides in urine samples before and after metastatic resection
Biospecimen Retention: Samples Without DNA
Urine
| Estimated Enrollment: | 45 |
| Study Start Date: | September 2012 |
| Estimated Study Completion Date: | March 2014 |
| Estimated Primary Completion Date: | March 2014 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
Patients
Patients with metastatic colorectal cancer scheduled for metastatic surgery
|
|
Control patients
Patients with metastatic colorectal cancer scheduled for general anesthesia without metastatic surgery
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
Patients with metastatic colorectal cancer treated at the Department of Medical Oncology of Paul Brousse Hospital
Criteria
Inclusion Criteria:
- Histologically-confirmed metastatic colorectal cancer;
- 0 to 3 prior chemotherapy lines; Signed informed consent;
- Good understanding of the protocol and of the follow-up;
- Estimated life expectancy exceeding 3 months;
- At least one measurable metastatic lesion (RECIST criteria);
- Performance Status (WHO) of 0 to 2;
- Good haematological, hepatic and renal functions.
Exclusion Criteria:
- Poor haematological, hepatic or renal functions;
- Uncontrolled chronic disease;
- Serious unhealed wound, ulcer or fracture within the previous month;
- Clinical or laboratory finding suggesting possible abnormalities in nucleosides urinary excretion;
- Pregnancy or breast-feeding during the previous month;
- Transmeridian trip of more than 4 time zones within the prior 2 weeks;
- Person with legal restriction to participate into clinical research, according to the current law in France.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01693848
Contacts
| Contact: Francis Levi, MD PhD | +33145593595 | francis.levi@inserm.fr |
| Contact: Sandrine Dulong, PhD | +33149583479 | sandrine.dulong@inserm.fr |
Locations
| France | |
| Paul Brousse hospital | Recruiting |
| Villejuif, France, 94800 | |
| Contact: Sandrine Dulong, PhD +33149583479 sandrine.dulong@insserm.fr | |
| Contact: Abdoulaye Karaboué, MD +33145593553 abdoulaye.karaboue@inserm.fr | |
| Principal Investigator: Francis Lévi, MD PhD | |
| Sub-Investigator: Rene Adam, MD PhD | |
| Sub-Investigator: Pasquale Innominato, MD PhD | |
| Sub-Investigator: Eric Viber, MD | |
Sponsors and Collaborators
Institut National de la Santé Et de la Recherche Médicale, France
More Information
No publications provided
| Responsible Party: | Institut National de la Santé Et de la Recherche Médicale, France |
| ClinicalTrials.gov Identifier: | NCT01693848 History of Changes |
| Other Study ID Numbers: | C11-58, 2012-A00011-42 |
| Study First Received: | September 7, 2012 |
| Last Updated: | September 24, 2012 |
| Health Authority: | France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis) |
Keywords provided by Institut National de la Santé Et de la Recherche Médicale, France:
|
Colorectal Cancer Metastatic Control Urine |
Nucleosides Surgery General anesthesia Scheduled for surgery |
Additional relevant MeSH terms:
|
Colorectal Neoplasms Neoplasm Metastasis Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms |
Digestive System Diseases Gastrointestinal Diseases Colonic Diseases Intestinal Diseases Rectal Diseases Neoplastic Processes Pathologic Processes |
ClinicalTrials.gov processed this record on May 23, 2013